Evidence map›Paper›PMID 40510304›Full record

ArticleJournal of biomedical physics & engineering2025

Breakthrough Infection and Death after COVID-19 Vaccination: A Physics Perspective.

Seyed Ali Reza Mortazavi, Abdollah Jafarzadeh, Abdolkarim Ghadimi-Moghadam, Seyed Mohammad Javad Mortazavi, Masoud Haghani, Ali Ghadimi-Moghadam, Lembit Sihver

Abstract read
In one paragraph

Article in Journal of biomedical physics & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Seyed Ali Reza MortazaviMVLS College, The University of Glasgow, Glasgow, Scotland, UK.
Abdollah JafarzadehDepartment of Immunology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Abdolkarim Ghadimi-MoghadamYasuj University of Medical Sciences, Yasuj, Iran.
Seyed Mohammad Javad MortazaviDepartment of Medical Physics and Engineering, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Masoud HaghaniDepartment of Radiology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali Ghadimi-MoghadamFaculty of Medicine, Szeged University, Szeged, Hungary.
Lembit SihverDepartment of Informatics and Engineering Systems, College of Engineering and Computer Science, University of Texas Rio Grande Valley, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The largest universal immunization in history has occurred as a result of the COVID-19 pandemic. The developed COVID-19 vaccines have been shown to provide protection against severe forms of COVID-19 by inducing anti-spike neutralizing antibodies. It has been found that individuals who have not been vaccinated against COVID-19 were more likely to contract the virus during a period when the Delta variant was dominant, as compared to those who have received the complete dose of the vaccine, irrespective of the variant. However, there is no notable disparity in the likelihood of hospitalization, requirement for mechanical ventilation, or mortality between the two groups once infected. Nevertheless, those who are unvaccinated may require additional oxygen support. There are reports indicating unfavorable health effects, ranging from transient thyroid dysfunction to death following vaccination. In addition, some people are susceptible to SARS-CoV-2 infection despite they have immunized with the COVID-19 vaccine. Given all these considerations, several key factors should be better understood and considered to enable us to even more successfully manage future pandemics breakthrough infections. The effectiveness of physical treatment methods, e.g., Low Dose Radiation Therapy (LDRT) should be compared to pharmacological treatments.

Indexed as

COVID-19Cytokine StormMedical PhysicsSARS-CoV-2Vaccines

Identifiers

PMID40510304
PMCPMC12153496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.